Poseida Therapeutics, Inc. Quarterly Income Tax Expense (Benefit) in USD from Q3 2022 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Poseida Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q3 2022 to Q3 2024.
  • Poseida Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $43K, a 59.8% decline year-over-year.
  • Poseida Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $107K, a 80.3% decline from 2022.
  • Poseida Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $544K.
  • Poseida Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was $0.000.
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $43K -$64K -59.8% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q3 2023 $107K -$145K -57.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q3 2022 $252K Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.